Abstract
The role of the vasoactive peptide endothelin-1 (ET-1) in renal injury is not fully understood. In this review, we examine the genetic models available to understand the autocrine/paracrine mechanisms by which ET-1 leads to renal injury and propose the working hypothesis that endothelium-derived ET-1 induces renal injury by initiating renal tubular apoptosis in a paracrine manner.
Keywords: endothelin-1, apoptosis, renal injury
endothelin-1 (ET-1) is an endogenous 21 amino acid peptide that has powerful vasoactive properties. ET-1 is produced by many cell types including endothelial cells (40), cardiomyocytes (36), mesangial cells (31), and different segments of the nephron, especially collecting ducts (22). Increased activity of the ET-1 system has been described in several cardiovascular and renal diseases (25, 28). ET-1 stimulates two G protein-coupled receptor subtypes, ETA and ETB receptors, with the same affinity for both receptors (7). Activation of each receptor subtype leads to different, and often opposite, physiological and pathophysiological results (3). Renal cortical and inner medullary tubules are rich in ETB receptors, whereas outer medullary tubules express both ETA and ETB receptors. Overactivation of the renal ETA pathway leads to hypertrophy, inflammation, and fibrosis. Actions of the ETB pathway promote clearance of ET-1 from circulation, stimulation of nitric oxide, and/or prostacyclin release, as well as increased sodium and water excretion (23). Several cell-type-specific endothelin pathway knockout mouse models and an ETB receptor-deficient rat model facilitate in-depth investigations into the activation of cellular source(s) and actions of ET-1. This review highlights the rationale for the use of genetic rodent models to elucidate the autocrine and/or paracrine mechanisms of ET-1-dependent development of renal apoptosis and injury. Based on the literature and our own preliminary findings, studying tunicamycin-induced renal apoptosis in two ET-1 genetic rodent models provides rationale for a working hypothesis that endothelium-derived ET-1 induces renal tubular apoptosis by a paracrine mechanism.
ET-1 Pathway, Apoptosis, and Renal Injury
Renal injury is preceded by tubular apoptosis and loss of nephrons (26). Apoptotic cell death is characterized by a series of changes in cellular morphology, such as shrinkage of the cell membrane, condensation of nuclear chromatin, cellular fragmentation, and engulfment of the apoptotic bodies by neighboring cells (21). Different vasoactive peptides have been implicated in the regulation of cellular apoptosis; however, contradictory reports in the literature do not provide a clear role of ET-1 in apoptosis and renal injury. Some studies indicate that ET-1 attenuates apoptosis in vascular smooth muscle cells (39), endothelial cells (11), and fibroblasts (33), whereas others describe pro-apoptotic effects of ET-1 in vascular smooth cells (5) or different areas of the kidney such as glomeruli, tubular cells, and interstitial cells (17).
Part of the confusion regarding the role of the endothelin pathway in apoptosis may be related to the conditions under study and the ET receptors involved. Several publications report that ETA receptor activation promotes cell proliferation and cell survival in a rat model of polycystic kidney disease (PKD) (16) during kidney development (41), in vascular smooth muscle cells (34), or in cardiomyocytes (27), whereas others describe pro-apoptotic effects of the ETA receptor in a model of chronic renovascular disease (19). Furthermore, ETB-selective agonists decreased apoptosis in rat endothelial cells (33) and ETB antagonists lead to increased apoptosis in rat and human endothelial cells (11, 32). Cancer studies show that activation of the ETB receptor is considered a survival mechanism (24), whereas the inhibition or loss of the ETB receptor is protective against apoptosis in renal tubular cells of a mouse model of PKD (6) or neurons subjected to hypoxia-ischemia (35). It is clear from all these reports that the ET pathway is involved and that a better understanding of the mechanisms by which ET-1 leads to renal injury, especially renal apoptosis, is needed. Thus utilizing a variety of genetic models would be advantageous for the study of ET-1-dependent mechanisms in renal apoptosis and injury.
Genetic Rodent Models: ET-1/ETA Pathway Versus ET-1/ETB Pathway
To better dissect the role of each of the components of the ET-1 system in the development of cardiovascular and renal disease, several genetic modifications have been performed in laboratory rodents (for review see Ref. 23). In 2010, a vascular endothelial cell ET-1 knockout mouse (VEET KO) was created (20). The VEET KO mouse has reduced plasma ET-1 concentrations and reduced ET-1 expression in vascular segments. Experiments using this model have shown that vascular endothelium-derived ET-1 mediates vascular inflammation and neointima formation in atherosclerosis (2), promotes cardiac fibrosis in diabetes (38), and stimulates glomerular formation of reactive oxygen species in response to high-salt diet or hypoxia (15).
Several genetic rodent models were generated to better understand the differential roles of the ETA and ETB receptors. For instance, rats without a functional ETB receptor display endothelial dysfunction (30) and salt-sensitive hypertension (12) via overactivation of ETA receptors (29). In addition, Kohan et al. demonstrated that collecting duct-specific knockout of ET-1 or the ETB receptor, but not the ETA receptor, leads to hypertension, sodium retention (1), and decreased plasma vasopressin levels (13). These studies highlight the importance of the ET-1/ETB pathway in the collecting duct as a physiological regulator of ENaC activity (4, 14) and systemic blood pressure. Interestingly, specific vascular smooth muscle disruption of the ETA receptor in mice leads to reduced blood pressure responses to high-salt diet and reduced vascular reactivity, highlighting the important role of this receptor in mediating the ET-1-induced vasoconstriction (10). An important question is the degree to which the loss of ETB receptor function results in elevated ETA-dependent effects that are unopposed.
Working Hypothesis: Endothelium-Derived ET-1 Mediates Renal Tubular Apoptosis
ET-1 is released from the basolateral cellular side highlighting the role of this peptide as an autocrine/paracrine factor (37). Recently, Widyantoro et al. (38) reported that endothelium-derived ET-1 is necessary for the development of cardiac fibrosis during diabetes, further emphasizing the paracrine actions of ET-1 and its role in tissue damage. Preliminary evidence from our laboratory show that control mice treated overnight with tunicamycin have significant levels of apoptosis in the outer medullary tubules, but not in renal vessels (9). We found that the outer medullary tubules of VEET KO mice are protected against the development of apoptosis in response to tunicamycin (9), indicating a role for the pro-apoptotic effects of endothelium-derived ET-1 on kidney tubular cells in a paracrine manner. Moreover, given that the outer medulla expresses ETA receptors, these studies suggest that the ETA receptor is pro-apoptotic in this particular rodent model. Tunicamycin can induce endoplasmic reticulum (ER) stress- and mitochondrial-mediated apoptosis (18), although the direct involvement of ET-1 was not tested in this study. Using the ETB-deficient rat as an experimental model, our group previously reported that pharmacological blockade of the ETA receptor ameliorates tunicamycin-induced renal ER stress and apoptosis in transgenic control rats, while failing to do so in the ETB-deficient rats (8). These results highlight the critical role of ETA receptor activation in renal apoptosis as well as the protective effect of the ETB receptor against tunicamycin-induced renal apoptosis. Interestingly, acute treatment with tunicamycin did not alter circulating ET-1 levels. Based on our preliminary results and information from the literature, we propose the working hypothesis that activation of endothelium-derived ET-1 induces renal tubular apoptosis in a paracrine manner (Fig. 1).
Fig. 1.

Working hypothesis. Vascular endothelium-derived endothelin-1 (ET-1) mediates renal injury in cardiovascular disease by inducing tubular apoptosis.
Perspectives and Significance
To test our proposed hypothesis, our laboratory will utilize the VEET KO mouse model with pharmacological blockade of the ETA and ETB receptors to assess the effect on tunicamycin-induced renal apoptosis. We will further differentiate between the actions of renal or nonrenal sources of ET-1 in the development of tunicamycin-induced renal apoptosis with renal transplantation studies in flox control and VEET KO mice. The preliminary results and the proposed studies with genetic models will determine the potential therapeutic value of targeting the endothelial ET-1 system to prevent the development of renal injury and apoptosis.
GRANTS
The authors acknowledge the grant support from National Institutes of Health T32 DK007545 to C. De Miguel and P01 HL95499, P01 HL69999 and U01 HL117684 to D. M. Pollock and J. S. Pollock.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the author(s).
AUTHOR CONTRIBUTIONS
Author contributions: C.D.M. and J.S.P. conception and design of research; C.D.M. performed experiments; C.D.M. analyzed data; C.D.M., D.M.P., and J.S.P. interpreted results of experiments; C.D.M. prepared figures; C.D.M. and J.S.P. drafted manuscript; C.D.M., D.M.P., and J.S.P. edited and revised manuscript; C.D.M., D.M.P., and J.S.P. approved final version of manuscript.
REFERENCES
- 1.Ahn D, Ge Y, Stricklett PK, Gill P, Taylor D, Hughes AK, Yanagisawa M, Miller L, Nelson RD, Kohan DE. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest 114: 504–511, 2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Anggrahini D, Emoto N, Nakayama K, Widyantoro B, Adiarto S, Iwasa N, Nonaka H, Kisanuki YY, Yanagisawa M, Hirata K. Vascular endothelial cell-derived endothelin-1 mediates vascular inflammation and noeintima formation following blood flow cessation. Cardiovasc Res 82: 143–151, 2009. [DOI] [PubMed] [Google Scholar]
- 3.Boesen E. Endothelin receptors, renal effects and blood pressure. Curr Opinion Pharmacol 21: 25–34, 2015. [DOI] [PubMed] [Google Scholar]
- 4.Bugaj VME, Kohan DE, Stockand JD. Collecting duct-specific endothelin B receptor knockout increase ENaC activity. Am J Physiol Cell Physiol 302: C188–C194, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Cattaruzza M, Dimigen C, Ehrenreich H, Hecker M. Stretch-induced endothelin B receptor mediated apoptosis invascular smooth muscle cells. FASEB J 14: 991–998, 2000. [DOI] [PubMed] [Google Scholar]
- 6.Chang MYPE, El Nahas M, Haylor JL, Ong AC. Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease. J Am Soc Nephrol 18 560–569, 2007. [DOI] [PubMed] [Google Scholar]
- 7.Davenport A, D'Orléans-Juste P, Godfraind T, Maguire JJ, Ohlstein EH, Ruffolo RR. Endothelin Receptors. International Union of Basic and Clinical Pharmacolgy (IUPHAR) database (IUPHAR-DB). Last modified on 04/07/15. Accessed on 30/04/20. http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=219. [Google Scholar]
- 8.De Miguel C, Hobbs J, Pollock DM, Pollock J. Renal endoplasmic reticulum stress is induced via endothelin A receptor activation. FASEB J 28: 857 857, 2014. [Google Scholar]
- 9.De Miguel C, Rodriguez MA, Pollock DM, Pollock JS. Evidence that vascular endothelial derived endothelin-1 promotes development of tunicamycin-induced endoplasmic reticulum stress in renal vessels. FASEB J. In press.
- 10.Donato A, Lesniewski LA, Stuart D, Walker AE, Henson G, Sorensen L, Li D, Kohan DE. Smooth muscle specific disruption of the endothelin-A receptor in mice reduces arterial pressure, and vascular reactivity and affects vascular development. Life Sci 24: 2, 2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Dong FZX, Wold LE, Ren Q, Zhang Z, Ren J. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol 145: 323–333, 2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Gariepy C, Ohuchi T, Williams SC, Richardson JA, Yanagisawa M. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 105: 925–933, 2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ge Y, Ahn D, Stricklett PK, Hughes AK, Yanagisawa M, Verbalis JG, Kohan DE. Collecting duct-specific knockout of endothelin-1 alters vasopressin regulation of urine osmolality. Am J Physiol Renal Physiol 288: F912–F920, 2005. [DOI] [PubMed] [Google Scholar]
- 14.Ge Y, Bagnall A, Stricklett PK, Strait K, Webb DJ, Kotelevtsev Y, Kohan DE. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol 291: F1274–F1280, 2006. [DOI] [PubMed] [Google Scholar]
- 15.Heimlich J, Speed JS, Bloom CJ, O'Connor PM, Pollock JS, Pollock DM. ET-1 increases reactive oxygen species following hypoxia and high-salt diet in the mouse glomerulus. Acta Physiol (Oxf) 213: 722–730, 2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Hocher B, Kalk P, Slowinski T, Godes M, Mach A, Herzfeld S, Wiesner D, Arck PC, Neumayer HH, Nafz B. ETA receptor blockade induces tubular cell proliferation and cyst growth in rats with polycystic kidney disease. J Am Soc Nephrol 14: 367–376, 2003. [DOI] [PubMed] [Google Scholar]
- 17.Hocher B, Rohmeiss P, Thone-Reineke C, Schwarz A, Burst V, van der Woude F, Bauer C, Theuring F. Apoptosis in kidneys of endothelin-1 transgenic mice. J Cardiovasc Pharmacol 31: S554–S556, 1998. [DOI] [PubMed] [Google Scholar]
- 18.Hodeify R, Megyesi J, Tarcsafalvi A, Mustafa HI, Hti Lat Seng NS, Proce PM. Gender differences control the susceptibility to ER stress-induced acute kidney injury. Am J Physiol Renal Physiol 304: F875–F882, 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Kelsen S, Hall JE, Chade AR. Endothelin-A receptor blockade slows the progression of renal injury in experimental renovascular disease. Am J Physiol Renal Physiol 301: F218–F225, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Kisanuki Y, Emoto N, Ohuchi T, Widyantoro B, Yagi K, Nakayama K, Kedzierski RM, Hammer RE, Yanagisawa H, Williams SC, Richardson JA, Suzuki T, Yanagisawa M. Low blood pressure in endothelial cell-specific endothelin 1 knockout mice. Hypertension 56: 121–128, 2010. [DOI] [PubMed] [Google Scholar]
- 21.Kockx M. Apoptosis in the atherosclerotic plaque quantitative and qualitative aspects. Arterioscler Thromb Vasc Biol 18: 1519–1522, 1998. [DOI] [PubMed] [Google Scholar]
- 22.Kohan D. Endothelin synthesis by rabbit renal tubule cells. Am J Physiol Renal Fluid Electrolyte Physiol 261: F221–F226, 1991. [DOI] [PubMed] [Google Scholar]
- 23.Kohan D, Inscho EW, Wesson D, Pollock DM. Physiology of endothelin and the kidney. Compr Physiol 1: 883–919, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Lahav R, Suvà ML, Rimoldi D, Patterson PH, Stamenkovic I. Endothelin receptor B inhibition triggers apoptosis and enhances angiogenesis in melanomas. Cancer Res 64: 8945–8953, 2004. [DOI] [PubMed] [Google Scholar]
- 25.Lankhorst S, Kappers MH, van Esch JH, Danser AH, van den Meiracker AH. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. J Hypertens 31: 444–454, 2013. [DOI] [PubMed] [Google Scholar]
- 26.Metcalfe W. How does early chronic kidney disease progress? A background paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease. Nephrol Dial Transplant 22: ix26–ix30, 2007. [DOI] [PubMed] [Google Scholar]
- 27.Ogata Y, Takahashi M, Ueno S, Takeuchi K, Okada T, Mano H, Ookawara S, Ozawa K, Berk BC, Ikeda U, Shimada K, Kobayashi E. Antiapoptotic effect of endothelin-1 in rat cardiomyocytes in vitro. Hypertension 41: 1156–1163, 2003. [DOI] [PubMed] [Google Scholar]
- 28.Orisio S, Benigni A, Bruzzi I, Corna D, Perico N, Zoja C, Benatti L, Remuzzi G. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 43: 354–358, 1993. [DOI] [PubMed] [Google Scholar]
- 29.Pollock J, Pollock DM. Endothelin and NOS1/nitric oxide signaling and regulation of sodium homeostasis. Curr Opin Nephrol Hypertens 17: 70–75, 2008. [DOI] [PubMed] [Google Scholar]
- 30.Quaschning T, Rebhan B, Wunderlich C, Wanner C, Richter CM, Pfab T, Bauer C, Kraemer-Guth A, Galle J, Yanagisawa M, Hocher B. Endothelin B receptor-deficient mice develop endothelial dysfunction independently of salt loading. J Hypertens 23: 979–985, 2005. [DOI] [PubMed] [Google Scholar]
- 31.Sakamoto J, Sakai S, Hirata Y, Imai T, Ando K, Ida T, Sakurai T, Yanagisawa M, Masaki T, Marumo F. Production of endothelin-1 by rat cultured mesangial cells. Biochem Biophys Res Commun 169: 462–468, 1990. [DOI] [PubMed] [Google Scholar]
- 32.Shichiri M, Kato H, Marumo F, Hirata Y. Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells. Hypertension 30: 1198–1203, 1997. [DOI] [PubMed] [Google Scholar]
- 33.Shichiri M, Sedivy JM, Marumo F, Hirata Y. Endothelin-1 is a potent survival factor for c-Myc-dependent apoptosis. Mol Endocrinol 12: 172–180, 1998. [DOI] [PubMed] [Google Scholar]
- 34.Shichiri M, Yokokura M, Marumo F, Hirata Y. Endothelin-1 inhibits apoptosis of vascular smooth muscle cells induced by nitric oxide and serum deprivation via MAP kinase pathway. Arterioscler Thromb Vasc Biol 20: 989–997, 2000. [DOI] [PubMed] [Google Scholar]
- 35.Sirén A, Lewczuk P, Hasselblatt M, Dembowski C, Schilling L, Ehrenreich H. Endothelin B receptor deficiency augments neuronal damage upon exposure to hypoxia-ischemia in vivo. Brain Res 945: 144–149, 2002. [DOI] [PubMed] [Google Scholar]
- 36.Tønnessen T, Giaid A, Saleh D, Naess PA, Yanagisawa M, Christensen G. Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. Circ Res 5: 767–772, 1995. [DOI] [PubMed] [Google Scholar]
- 37.Wagner O, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhäusl W, Binder BR. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267: 16066–16068, 1992. [PubMed] [Google Scholar]
- 38.Widyantoro B, Emoto N, Nakayama K, Anggrahini DW, Adiarto S, Iwasa N, Yagi K, Miyagawa K, Rikitake Suzuki T, Kisanuki YY, Yanagisawa M, Hirata K. Endothelial-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 121: 2407–2418, 2010. [DOI] [PubMed] [Google Scholar]
- 39.Wu-Wong J, Chiou WJ, Dickinson R, Opgenorth TJ. Endothelin attenuates apoptosis in human smooth muscle cells. Biochem J 328: 733–737, 1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yasaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411–415, 1988. [DOI] [PubMed] [Google Scholar]
- 41.Yoo K, Yim HE, Jang GY, Bae IS, Choi BM, Hong YS, Lee JW. Endothelin A receptor blockade influences apoptosis and cellular proliferation in the developing rat kidney. J Korean Med Sci 24: 138–145, 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
